Implantable Cardioverter-Defibrillators in Sudden Cardiac Death Survivors: Are We Doing All We Can?

2017 ◽  
Vol 33 (10) ◽  
pp. 1215-1216 ◽  
Author(s):  
Ratika Parkash ◽  
Anthony S.L. Tang
Keyword(s):  
Sudden Cardiac Death ◽  
Cardiac Death ◽  
Implantable Cardioverter Defibrillators ◽  
Cardioverter Defibrillators

scholarly journals Prophylactic Use of Implantable Cardioverter-Defibrillators in the Prevention of Sudden Cardiac Death in Dialysis Patients

Circulation ◽  
2019 ◽  
Vol 139 (23) ◽  
pp. 2628-2638 ◽  
Author(s):  
J. Wouter Jukema ◽  
Rohit J. Timal ◽  
Joris I. Rotmans ◽  
Liselotte C. R. Hensen ◽  
Maurits S. Buiten ◽  
...  
Keyword(s):  
Sudden Cardiac Death ◽  
Cardiac Death ◽  
Implantable Cardioverter Defibrillators ◽  
Dialysis Patients ◽  
Prophylactic Use ◽  
Cardioverter Defibrillators

scholarly journals Modern pacemaker therapy

2010 ◽  
Vol 63 (11-12) ◽  
pp. 822-826
Author(s):  
Dragan Kovacevic ◽  
Vasilije Topalov ◽  
Milan Mijatov
Keyword(s):  
Heart Failure ◽  
Sudden Cardiac Death ◽  
Cardiac Death ◽  
Modern Medicine ◽  
Implantable Cardioverter Defibrillators ◽  
Bundle Branch Block ◽  
Pacemaker Therapy ◽  
Patients With Heart Failure ◽  
Cardioverter Defibrillators

Introduction. Pacemakers are devices that modern medicine and cardiology cannot be imagined without. The technique of implantation comes to surgical procedure where all principles of asepsis and antisepsis have to be respected. Although some complications do happen, they are rather rare. Results. After the implantation of the device, the patient is not handicapped (unless the heart was additionally damaged). On the contrary, the patient returns to his work and functions normally within his family in most of the cases. The first medical appointment is scheduled a month after the implantation and the following are three and six months after. Types of devices. Today there are ?new types of electrostimulation?- implantable cardioverter defibrillators and multisite electrostimulators. The former is implanted in patients at high risk of sudden cardiac death and the latter in patients with heart failure and left bundle branch block. Owing to these devices, the sudden cardiac death can be prevented successfully and the quality of a patient?s life is improved.

Ventricular Arrhythmias: Antiadrenergic Therapy for the Patient with Coronary Artery Disease

2005 ◽  
Vol 10 (4_suppl) ◽  
pp. S23-S31 ◽  
Author(s):  
Stefan H. Hohnloser
Keyword(s):  
Sudden Cardiac Death ◽  
Cardiac Death ◽  
Ventricular Arrhythmias ◽  
Clinical Evidence ◽  
Synergistic Effects ◽  
Implantable Cardioverter Defibrillators ◽  
Patients At Risk ◽  
Adrenergic Blockers ◽  
Artery Disease ◽  
Cardioverter Defibrillators

Patients who have had a recent myocardial infarction (MI) are at high risk of ventricular arrhythmias that often cause sudden cardiac death. It is believed that sympathetic overactivity in the peri-infarction period may alter the electrophysiology and structure of the myocardium, thus placing these patients at risk of developing rhythm disturbances. A number of pharmacologic and nonpharmacologic therapies have been shown to reduce the risk of post-MI mortality, including sudden cardiac death. β-Adrenergic blockers are recommended for all post-MI patients without contraindications because of overwhelming clinical evidence of their benefit in reducing mortality in this patient population. Recent clinical trials of implantable cardioverter defibrillators have provided compelling support that they are effective in both the primary and secondary prevention of sudden cardiac death. In addition, several studies have shown that combination therapy with β-blockers and implantable cardioverter defibrillators have synergistic effects that optimize the benefits of both therapies.

Sign in / Sign up

Export Citation Format

Share Document